FI963916A - Uudet stabiloidut galeeniset formulaatiot, jotka sisältävät happolabiilia bentsimidatsoliyhdistettä, ja niiden valmistus - Google Patents

Uudet stabiloidut galeeniset formulaatiot, jotka sisältävät happolabiilia bentsimidatsoliyhdistettä, ja niiden valmistus Download PDF

Info

Publication number
FI963916A
FI963916A FI963916A FI963916A FI963916A FI 963916 A FI963916 A FI 963916A FI 963916 A FI963916 A FI 963916A FI 963916 A FI963916 A FI 963916A FI 963916 A FI963916 A FI 963916A
Authority
FI
Finland
Prior art keywords
preparation
acid
formulations containing
benzimidazole compound
galenic formulations
Prior art date
Application number
FI963916A
Other languages
English (en)
Swedish (sv)
Other versions
FI121730B (fi
FI963916A0 (fi
Inventor
Rodes Montserrat Ballester
Boven Marius Van
Original Assignee
Esteve Quimica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8289322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI963916(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Quimica Sa filed Critical Esteve Quimica Sa
Publication of FI963916A publication Critical patent/FI963916A/fi
Publication of FI963916A0 publication Critical patent/FI963916A0/fi
Application granted granted Critical
Publication of FI121730B publication Critical patent/FI121730B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI963916A 1995-02-01 1996-09-30 Uudet stabiloidut galeeniset formulaatiot, jotka sisältävät happolabiilia bentsimidatsoliyhdistettä, ja niiden valmistus FI121730B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES09500181A ES2094694B1 (es) 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
ES9500181 1995-02-01
PCT/ES1996/000013 WO1996023500A1 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion
ES9600013 1996-01-26

Publications (3)

Publication Number Publication Date
FI963916A true FI963916A (fi) 1996-09-30
FI963916A0 FI963916A0 (fi) 1996-09-30
FI121730B FI121730B (fi) 2011-03-31

Family

ID=8289322

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963916A FI121730B (fi) 1995-02-01 1996-09-30 Uudet stabiloidut galeeniset formulaatiot, jotka sisältävät happolabiilia bentsimidatsoliyhdistettä, ja niiden valmistus

Country Status (20)

Country Link
US (1) US5626875A (fi)
EP (2) EP0773025B1 (fi)
JP (1) JP4183746B2 (fi)
KR (1) KR100331290B1 (fi)
AR (1) AR002702A1 (fi)
AT (2) ATE292967T1 (fi)
AU (1) AU4540396A (fi)
CA (1) CA2184842C (fi)
DE (3) DE69634613T2 (fi)
DK (2) DK0773025T3 (fi)
ES (3) ES2094694B1 (fi)
FI (1) FI121730B (fi)
HU (1) HU229219B1 (fi)
IL (1) IL116673A (fi)
IN (1) IN186596B (fi)
PT (2) PT993830E (fi)
SI (2) SI0773025T1 (fi)
TW (1) TW503115B (fi)
WO (1) WO1996023500A1 (fi)
ZA (1) ZA96683B (fi)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
ATE262332T1 (de) * 1995-09-21 2004-04-15 Pharma Pass Ii Llc Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
FR2774288B1 (fr) † 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
WO1999053918A1 (fr) 1998-04-20 1999-10-28 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
SI1105105T1 (sl) * 1998-08-12 2006-08-31 Altana Pharma Ag Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
WO2001028559A1 (fr) 1999-10-20 2001-04-26 Eisai Co., Ltd. Procede de stabilisation de composes benzimidazoles
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ATE297194T1 (de) * 1999-12-16 2005-06-15 Medinfar Produtos Farmaceutico Neue stabile mehreinheitliche substituierte benzimidazole enthaltende pharmazeutische präparate
US6419956B1 (en) 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
EP1341529A2 (en) * 2000-11-10 2003-09-10 F. Hoffman-la Roche AG Hydrolytically unstable compositions
AU2002314967B2 (en) * 2001-06-05 2007-09-20 University Of Chicago Use of methylnaltrexone to treat immune suppression
IL159854A0 (en) 2001-07-16 2004-06-20 Janssen Pharmaceutica Nv Improved process for preparing benzimidazole-type compounds
CN1596101A (zh) * 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 含有糖果组分的剂型
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
ES2198195B1 (es) 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
EP1524967B1 (en) * 2002-08-02 2008-03-12 Ratiopharm GmbH Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1594479A1 (en) * 2003-01-31 2005-11-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
WO2004091622A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
WO2004098573A1 (en) * 2003-05-08 2004-11-18 Natco Pharma Limited An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
ATE531361T1 (de) 2004-05-07 2011-11-15 Nycomed Gmbh Neue pharmazeutische dosierform und herstellungsverfahren
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
CN101111233A (zh) 2004-12-23 2008-01-23 兰贝克赛实验室有限公司 稳定的口服苯并咪唑组合物及其制备方法
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
MX2007008141A (es) * 2005-01-03 2007-12-10 Lupin Ltd Composicion farmaceutica de sustancias labiles en medio acido.
MX2007008756A (es) * 2005-01-20 2007-09-27 Progenics Pharm Inc Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1785135A1 (en) 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
EP1962844A2 (en) * 2005-12-20 2008-09-03 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
RU2467747C2 (ru) * 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
ES2620373T3 (es) 2008-07-01 2017-06-28 University Of Chicago Partículas que contienen un antagonista del receptor de opioides periférico
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
JP2011530569A (ja) * 2008-08-11 2011-12-22 メファ・ゲーエムベーハー 特定の分離層を含むオメプラゾールの経口医薬製剤
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
WO2011138797A2 (en) 2010-05-04 2011-11-10 Cadila Healthcare Limited Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
EP2773348B1 (en) * 2011-11-02 2018-02-21 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical composition of omeprazole
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
EP3718404A1 (en) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progession
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829055A (en) * 1958-02-07 1960-02-24 Charles E Frosst And Company Improvements in or relating to pharmaceutical preparations
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4470980A (en) * 1980-03-07 1984-09-11 Interx Research Corp. Method of increasing oral absorption of β-lactam antibiotics
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
JPS58208155A (ja) * 1982-05-28 1983-12-03 Sumitomo Electric Ind Ltd 光伝送用ガラスフアイバの製造方法
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5395611A (en) * 1990-04-24 1995-03-07 The Governors Of The University Of Alberta Phenolic amine depigmenting and antimelanoma agents
IT1241740B (it) * 1990-06-22 1994-02-01 Edi Bondioli Protezione per una forcella di estremita' di un albero cardanico
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process

Also Published As

Publication number Publication date
PT773025E (pt) 2000-10-31
EP0773025B1 (en) 2000-06-07
WO1996023500A1 (es) 1996-08-08
EP0993830B1 (en) 2005-04-13
ES2238796T3 (es) 2005-09-01
CA2184842C (en) 2007-08-07
IN186596B (fi) 2001-10-06
KR100331290B1 (ko) 2002-11-22
ZA96683B (en) 1997-09-23
HUP9603014A3 (en) 2000-12-28
JPH09511257A (ja) 1997-11-11
AR002702A1 (es) 1998-04-29
AU4540396A (en) 1996-08-21
FI121730B (fi) 2011-03-31
ES2094694A1 (es) 1997-01-16
ATE193649T1 (de) 2000-06-15
US5626875A (en) 1997-05-06
PT993830E (pt) 2005-06-30
ATE292967T1 (de) 2005-04-15
TW503115B (en) 2002-09-21
DK0993830T3 (da) 2005-08-08
DE29623938U1 (de) 2000-10-05
IL116673A0 (en) 1996-05-14
SI0993830T1 (en) 2005-10-31
ES2148725T3 (es) 2000-10-16
EP0773025A1 (en) 1997-05-14
EP0993830A3 (en) 2001-10-04
JP4183746B2 (ja) 2008-11-19
EP0993830A2 (en) 2000-04-19
HU229219B1 (en) 2013-09-30
HUP9603014A2 (hu) 1998-03-30
FI963916A0 (fi) 1996-09-30
DE69608767D1 (de) 2000-07-13
CA2184842A1 (en) 1996-08-08
DE69634613T2 (de) 2006-03-09
IL116673A (en) 2000-10-31
DE69634613D1 (de) 2005-05-19
DK0773025T3 (da) 2000-10-09
ES2094694B1 (es) 1997-12-16
SI0773025T1 (en) 2000-10-31

Similar Documents

Publication Publication Date Title
FI963916A0 (fi) Uudet stabiloidut galeeniset formulaatiot, jotka sisältävät happolabiilia bentsimidatsoliyhdistettä, ja niiden valmistus
FI973039A (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
ITRM910696A0 (it) Composizioni farmaceutiche per l'applicazione per via nasale.
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
KR970702720A (ko) 항간질 약물에 효과적인 제형(Effectice Dosage Form for Antiepileptic Drugs)
IT1246188B (it) Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
PT1001813E (pt) Formulacoes farmaceuticas contendo voriconazole
ITBO910024A0 (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale
FI935073A (fi) Nya tiopyranopyrrolderivat, framstaellning av dem och dessa innehaollande farmaceutiska sammansaettningar
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
FI971523A0 (fi) Bentsopyraani- ja bentsofuusioituja yhdisteitä, niiden valmistus ja käyttö leukotrieeni B4':n (LTB4) antagonisteina
ITBO970640A0 (it) Apparecchio per l'elettroemanazione di principi attivi.
SE8804628D0 (sv) New compounds
FI945780A0 (fi) Uudet biologisesti aktiiviset eburnameniinijohdannaiset, niitä sisältävät farmaseuttiset koostumukset ja menetelmä niiden valmistamiseksi
FI970095A0 (fi) Uudet kemialliset yhdisteet, niiden valmistus ja niiden käyttö lääkeaineena
ITRM910554A0 (it) Composizioni farmaceutiche stabilizzate
FI964900A0 (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
FI913888A (fi) Nya farmaceutiska sammansaettningar och foerfarande foer framstaellning av desamma.
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
FI930293A (fi) Nya heteroaryloxi-b-karboliner, deras framstaellning och anvaendning i laekemedel
FI970539A0 (fi) Foerfarande och anordning foer inmatning av luft i en sodapanna
FI972965A (fi) Uusia peptidejä, niiden valmistus ja käyttö
FI923304A (fi) Nya bearbetbara tiofenbaserade polymerer och kopolymerer, och vaermestabila elledande kompositioner daerav
DE69903914D1 (de) Herstellung von 3-buten-1-ol aus 3,4-epoxy-1-buten
IT1276684B1 (it) Formulazioni idrosolubili di collagenasi stabilizzata e procedimento per la loro preparazione

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: LABORATORIOS DR. ESTEVE S.A.

FG Patent granted

Ref document number: 121730

Country of ref document: FI

MM Patent lapsed